COMPOSITIONS COMPRISING NANOPARTICLES, METHOD OF MAKING AND USES THEREOF
Presented herein, in certain aspects, are cell-free therapeutic composition derived from human amniotic fluid (HAF) and uses thereof for the prevention and treatment of selected diseases and disorders.
1 . A method of a treating traumatic brain injury in a subject, the method comprising:
administering to the subject having a traumatic brain injury a therapeutically effective amount of a composition comprising:
(a) a modified human amniotic fluid (HAF); and
(b) HAF-derived nanoparticles, the nanoparticles having a mode diameter of between 30 and 200 nm, and a concentration of the nanoparticles in the composition being at least 1×10 10 nanoparticles/mL,
wherein the modified HAF is substantially free of cells, pathogens, vernix, lanugo, and macroparticles, and
wherein the composition is administered via nebulization.
2 . The method of claim 1 , wherein the nanoparticles comprise extracellular vesicles.
3 . The method of claim 2 , wherein the nanoparticles comprise membrane-encapsulated extracellular vesicles.
4 . The method of claim 2 , a concentration of the extracellular vesicles being at least 10 pg/mL.
5 . The method of claim 1 , wherein the nanoparticles comprise exosomes.
6 . The method of claim 1 , wherein the composition is made by a process comprising:
(a) obtaining a volume of HAF;
(b) centrifuging the volume of HAF at 500×g for 10 minutes (min) to obtain a first supernatant;
(c) centrifuging the first supernatant at 2000×g for 30 min to obtain a second supernatant; and
(d) filtering at least a portion of the second supernatant using a 0.22 uM filter.
7 . The method of claim 6 , wherein the composition comprises saline.
8 . The method of claim 6 , wherein the composition comprises a diluent.
9 . The method of claim 1 , the composition comprising at least at least 1×10 10 nanoparticles.
10 . The method of claim 1 , wherein the nanoparticles comprise at least three surface-bound proteins selected from the group consisting of CD9, CD63, CD81, CD326 and CD133.
11 . The method of claim 1 , wherein the nanoparticles comprise at least one miRNA selected from Table 1.
12 . The method of claim 1 , wherein the nanoparticles comprise annexin, heat shock proteins, and TSG101.
13 . The method of claim 1 , wherein the traumatic brain injury is a closed brain injury.
14 . The method of claim 1 , wherein the traumatic brain injury is a concussion.
15 . A method of a treating traumatic brain injury in a subject, the method comprising:
administering to the subject having a traumatic brain injury a therapeutically effective amount of a composition comprising:
(a) a modified human amniotic fluid (HAF); and
(b) HAF-derived nanoparticles, the nanoparticles having a mode diameter of between 30 and 200 nm, and a concentration of the nanoparticles in the composition being at least 1×10 10 nanoparticles/mL,
wherein the modified HAF is substantially free of cells, pathogens, vernix, lanugo, and macroparticles, and
wherein the composition is administered via at least one administration method, the at least one administration method selected from the group consisting of aerosolization, intra-nasal delivery, inhalation, and intravenous infusion.
16 . The method of claim 15 , wherein the nanoparticles comprise extracellular vesicles.
17 . The method of claim 15 , wherein the composition is made by a process comprising:
(a) obtaining a volume of HAF;
(b) centrifuging the volume of HAF at 500×g for 10 minutes (min) to obtain a first supernatant;
(c) centrifuging the first supernatant at 2000×g for 30 min to obtain a second supernatant; and
(d) filtering at least a portion of the second supernatant using a 0.22 uM filter.
18 . The method of claim 15 , the composition comprising at least at least 1×10 10 nanoparticles.
19 . The method of claim 15 , wherein the nanoparticles comprise annexin, heat shock proteins, and TSG101.
20 . The method of claim 15 , wherein the nanoparticles comprise at least three surface-bound proteins selected from the group consisting of CD9, CD63, CD81, CD326 and CD133.
21 . The method of claim 15 , wherein the nanoparticles comprise at least one miRNA selected from Table 1.